Harrow Health announced that the company will relocate its headquarters from San Diego to Nashville, Tennessee.
“From our new home in Nashville, our team will continue to start, finance and grow pharmaceutical companies that will develop innovative, affordable and accessible medicines to solve the unmet needs of Americans,” Harrow Health Founder and CEO Mark L. Baum said in a company news release. “Our team is grateful for the warm welcome we’ve received from everyone in Tennessee, from the Governor and legislators, who have created a business climate that is second to none, to our new neighbors in Nashville where our families will live. Our team is excited to contribute to the future of Tennessee.”
Harrow Health, formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company. Its prime business model has been compounding drugs. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, companies founded as subsidiaries of Harrow Health.